This article is more than 5 years old. Information may no longer be current.
Prompt treatment of wet AMD may improve visual outcome
Click Here to Manage Email Alerts
Patients with neovascular age-related macular degeneration should be treated without delay to maximize visual outcome, according to a study.
“This study demonstrates that even short delays in treatment of new-onset wet AMD result in persistent loss of visual acuity. In this regard, delays in treating wet AMD should be avoided; in particular, the waiting period between diagnosis and treatment should be kept as short as possible,” the study authors said.
The retrospective review examined 45 patients with new-onset subfoveal choroidal neovascularization related to exudative AMD. Inclusion criteria required that study participants had received two intravitreal injections of ranibizumab at a 4-week interval and were able to state the onset and type of visual symptoms with precision.
Best corrected visual acuity, IOP, dilated fundus examination data and central retinal thickness were recorded at baseline and at 2 months. All patients were treated with ranibizumab injections at baseline and at 4 weeks.
Prior to initiating treatment, the mean BCVA was 0.33 ± 0.2. After receiving two ranibizumab injections 2 months later, the mean BCVA was 0.41 ± 0.2 (P = .001).
“Only patients with an estimated duration of <1 month showed a significant improvement in visual acuity, whereas the report of visual symptoms for 1 month to 6 months illustrated only modest visual results,” the authors said.
Click Here to Manage Email Alerts